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Introduction {#sec1}
============

As demonstrated 40 years ago, brain 5-hydroxytryptamine (5-HT; serotonin) is a significant regulator of appetite and body weight ([@bib6]). Targeting this neurochemical machinery, medications increasing 5-HT bioavailability were developed to treat obesity. However, increasing 5-HT activity at peripheral 5-HT receptors (5-HTRs) contributed to side effects that led to the withdrawal of medications such as d-fenfluramine in the 1990s and sibutramine in the 2000s ([@bib10]). Efforts to delineate 5-HTRs mediating 5-HT\'s therapeutic effects on food intake revealed the 2C receptor subtype (*Htr2cr*, 5-HT~2C~R) as the principal mediator ([@bib37], [@bib39]). The clinical significance of this discovery is underscored by a new obesity medication, the 5-HT~2C~R agonist, lorcaserin, which was recently launched in the United States ([@bib4], [@bib33]).

5-HT~2C~Rs are widely distributed within the brain where they act to modulate a diverse array of behaviors and physiological processes ([@bib10], [@bib24]). Of the neurochemically defined cells expressing 5-HT~2C~Rs, it is a subpopulation of neurons within the arcuate nucleus of the hypothalamus (ARC) that co-express the precursor polypeptide pro-opiomelanocortin (POMC) that have been proposed to be a principal mediator of 5-HT~2C~R\'s effects on metabolic functions ([@bib5], [@bib11], [@bib14], [@bib19], [@bib41]). However, anorectic doses of 5-HT~2C~R agonists have been shown to increase markers of neuronal activity in caudal brainstem regions, including the nucleus of the solitary tract (NTS) ([@bib28], [@bib35]). Although the NTS is a brainstem structure known to be a key regulatory center for the integration of food related signals of both peripheral and central origin ([@bib16], [@bib18], [@bib42]), no direct functional assessment of 5-HT~2C~Rs in this brain region has been undertaken. Here we probed the functional significance of 5-HT~2C~Rs within the NTS, their contribution to the therapeutic effect of 5-HT~2C~R agonist obesity medications, and the mechanism underpinning their appetite-reducing effect via exclusive action within the NTS.

Results {#sec2}
=======

Selective 5-HT~2C~R^NTS^ Neuron Activation Decreases Food Intake {#sec2.1}
----------------------------------------------------------------

To determine whether 5-HT~2C~R-expressing NTS (5-HT~2C~R^NTS^) neurons play a role in appetite control, we first employed the chemogenetic designer receptors exclusively activated by designer drugs (DREADDs; [@bib3]) approach to specifically express G~q~-coupled (hM3D~q~) or G~i~-coupled (hM4D~i~) designer receptors in 5-HT~2C~R^NTS^ neurons. To target 5-HT~2C~R^NTS^ neurons, we stereotactically delivered Cre-dependent adeno-associated viruses (AAVs) encoding designer receptor hM3D~q~ or hM4D~i~ into the NTS of *5-HT*~*2C*~*R*^*Cre*^ mice ([@bib9], [@bib11], [@bib29]) to generate *5-HT*~*2C*~*R*^*NTS*^-hM3D~q~ ([Figures 1](#fig1){ref-type="fig"}A and 1B) and *5-HT*~*2C*~*R*^*NTS*^-hM4D~i~ cohorts ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Cre recombinase activity in *5-HT*~*2C*~*R*^*Cre*^ mice efficiently recombined the DREADD-mCherry allele in the NTS, as seen by the expression of the mCherry reporter protein in transduced cells ([Figure 1](#fig1){ref-type="fig"}C). A degree of spread was observed in adjacent regions following amplification of mCherry signal with immunohistochemistry ([Figure 1](#fig1){ref-type="fig"}C). Following treatment with designer drug clozapine-N-oxide (CNO; 1 mg/kg, intraperitoneally \[i.p.\]), c-fos immunoreactivity (FOS-IR; a surrogate marker of neuronal activation) was observed within the NTS of *5-HT*~*2C*~*R*^*NTS*^-hM3D~q~ mice. In *5-HT*~*2C*~*R*^NTS^-hM3D~q~ mice that had been fasted overnight to decrease baseline FOS-IR, quantification analysis revealed that approximately 76.4% ± 3.7% of mCherry-positive NTS cells expressed FOS-IR following CNO treatment whereas less than 1% expressed FOS-IR following saline treatment ([Figure 1](#fig1){ref-type="fig"}C). Consistent with these *in vivo* data, in *ex vivo* NTS slices, bath application of CNO (10 μM) increased the firing frequency of *5-HT*~*2C*~*R*^NTS^-hM3D~q~-expressing neurons (n = 5/5; [Figure 1](#fig1){ref-type="fig"}D). These data indicate that CNO allows remote chemical control of 5-HT~2C~R^NTS^ neuronal activity in *5-HT*~*2C*~*R*^*NTS*^-hM3D~q~-expressing mice. We next examined the effect of CNO on feeding behavior. CNO (1 mg/kg, i.p.) significantly reduced the first 5 hr of *ad libitum* dark cycle chow intake compared with saline treatment in *5-HT*~*2C*~*R*^*NTS*^-hM3D~q~ mice ([Figure 1](#fig1){ref-type="fig"}E).Figure 1Activation of 5-HT~2C~R^NTS^-Expressing Neurons Reduces Food Intake(A) Schematic of the strategy used to selectively activate 5-HT~2C~R^NTS^ neurons; stereotactic injection of Cre-dependent DREADD vectors into NTS of *5-HT*~*2C*~*R*^*Cre*^ mice.(B) *5-HT*~*2C*~*R*^*Cre*^ construct and Cre-mediated recombination of DREADD allele.(C) Expression of the DREADD-fused mCherry reporter protein within the NTS using immunohistochemistry for mCherry (mCherry-IR; red). *In vivo*, CNO (1 mg/kg, intraperitoneally \[i.p.\]) increased FOS-IR (green) expression in the majority of *5-HT*~*2C*~*R*^NTS^-hM3D~q~-expressing neurons (red, bottom panels), whereas saline treatment did not (top panels).(D) *Ex vivo*, bath application of CNO (10 μM) increased the firing frequency of *5-HT*~*2C*~*R*^NTS^-hM3D~q~-expressing neurons.(E) CNO (1 mg/kg, i.p.) elicited a significant reduction in *ad libitum* dark cycle food intake compared with saline treatment in *5-HT*~*2C*~*R*^NTS^-hM3D~q~ mice (n = 6--7; 3 hr: t~12~ = 3.57, p = 0.004; 5 hr: t~12~ = 3.379, p = 0.005; 24 hr: t~12~ = 1.876, p = 0.0874). Data are presented as mean ± SEM. ^∗∗^p \< 0.01.NTS, nucleus of the solitary tract; AP, area postrema; CC, central canal. Scale bar, 200 μm. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Despite the CNO (10 μM)-induced reduction in membrane potential observed in *ex vivo* NTS slices from *5-HT*~*2C*~*R*^*NTS*^-hM4D~i~ mice (n = 5/5; [Figure S1](#mmc1){ref-type="supplementary-material"}C), CNO (1 mg/kg, i.p.) did not affect *ad libitum* food intake in *5-HT*~*2C*~*R*^*NTS*^-hM4D~i~ mice compared with saline ([Figure S1](#mmc1){ref-type="supplementary-material"}D). The effect of CNO on feeding behavior in *5-HT*~*2C*~*R*^NTS^-hM3D~q~ but not *5-HT*~*2C*~*R*^NTS^-hM4D~i~ mice illustrates that CNO is not altering food intake via action at endogenous receptors. Rather, the designer drug CNO is reducing food intake via action at the designer *5-HT*~*2C*~*R*^*NTS*^-hM3D~q~ receptors. These data reveal that activation of 5-HT~2C~R^NTS^ neurons significantly suppresses feeding and identifies a novel population of NTS cells that may be targeted for food intake reduction.

Selective 5-HT~2C~R^NTS/DMV^ Activation Is Sufficient to Promote 5-HT~2C~R Agonist Hypophagia {#sec2.2}
---------------------------------------------------------------------------------------------

We next evaluated whether an obesity medication currently in human use employs the subset of 5-HT~2C~R^NTS^ to promote a reduction in feeding behavior. To exclusively activate 5-HT~2C~R^NTS^ with clinical and preclinical obesity medications, we restricted the expression of the endogenous receptor to the caudal aspects of the dorsal vagal complex (the NTS and dorsal motor nucleus of the vagus \[DMV\]; *5-HT*~*2C*~*R*^*NTS/DMV*^). We achieved this using a reversible *5-HT*~*2C*~*R* null line, in which expression of *Htr2cr* is prevented by a loxP-flanked transcriptional blocker ([@bib40]). The expression of *Htr2cr* was site-specifically reactivated via stereotactic delivery of an AAV-expressing Cre recombinase (AAV-Cre) into the NTS/DMV, which removes the transcriptional blocker ([Figures 2](#fig2){ref-type="fig"}A and 2B), allowing 5-HT~2C~Rs expression only in the NTS/DMV ([Figures 2](#fig2){ref-type="fig"}C and 2D). To confirm the functional re-expression of *Htr2c*, we made *ex vivo* whole-cell electrophysiological recordings from neurons within NTS slices in *5-HT*~*2C*~*R*^*WT*^ (wild-type), *5-HT*~*2C*~*R*^*KO*^ (knockout), and mice with 5-HT~2C~Rs restored exclusively within the NTS/DMV (*5-HT*~*2C*~*R*^*NTS/DMV*^). As expected, NTS neurons from *5-HT*~*2C*~*R*^*KO*^ mice failed to respond to lorcaserin, while similar proportions of NTS neurons from *5-HT*~*2C*~*R*^*WT*^ and *5-HT*~*2C*~*R*^*NTS/DMV*^ mice were excited by lorcaserin ([Figure 2](#fig2){ref-type="fig"}E). These data indicate that AAV-Cre restores functional 5-HT~2C~R expression in *5-HT*~*2C*~*R*^*NTS/DMV*^ mice.Figure 25-HT~2C~R^NTS^ Is Sufficient to Mediate the Appetite-Suppressive Effect of 5-HT~2C~R Agonists(A) Schematic of the strategy used to selectively restore 5-HT~2C~Rs within the NTS of *loxTB5-HT*~*2C*~*R* null mice through stereotactic injection of Cre-dependent DREADD vectors into NTS.(B) *5-HT*~*2C*~*R* allele expression is disrupted by a loxP-flanked transcriptional blocker (loxTB) inserted between exons 3 and 4 of the *htr2c* gene in *loxTB5-HT*~*2C*~*R* mice (*5-HT*~*2C*~*R*^*KO*^). Stereotactic injection of AAV vector expressing Cre recombinase and mCherry reporter driven by the hSyn promoter removes the TB and allows 5-HT~2C~R expression only in the NTS (*5-HT*~*2C*~*R*^*NTS/DMV*^).(C) Representative image of Cre-mCherry expression within the rostrocaudal aspect of the NTS/DMV.(D) Cre-mediated recombination of the mutant allele and TB removal specifically within the NTS/DMV in *5-HT*~*2C*~*R*^*NTS/DMV*^ mice (wild-type band 437 bp, mutant 310 bp).(E) Representative current-clamp traces and proportion of neurons responding to bath application of lorcaserin in *ex vivo* NTS slices prepared from *5-HT*~*2C*~*R*^*WT*^ (n = 7), *5-HT*~*2C*~*R*^*KO*^ (n = 12), and *5-HT*~*2C*~*R*^*NTS/DMV*^ (n = 8) mice.(F) Sidak\'s post hoc comparisons revealed that lorcaserin and WAY161,503 (7 mg/kg, i.p.) reduced *ad libitum* food intake at specific time points within the first 3 hr of the dark cycle (tick marks on x axis represent 20-min intervals) in *5-HT*~*2C*~*R*^*WT*^ (lorcaserin, n = 5; time: F~6,24~ = 55.19, p \< 0.0001; treatment: F~1,4~ = 16.81, p = 0.0149; interaction: F~6,24~ = 8.991, p \< 0.0001. WAY161,503, n = 6; time: F~6,30~ = 53.37, p \< 0.0001; treatment: F~1,5~ = 61.55, p = 0.0005; interaction: F~6,30~ = 26.16, p \< 0.0001) and *5-HT*~*2C*~*R*^*NTS/DMV*^ mice (lorcaserin, n = 5; time: F~6,24~ = 63.53, p \< 0.0001; treatment: F~1,4~ = 23.78, p = 0.0082; interaction: F~6,24~ = 4.099, p = 0.0057. WAY161,503, n = 6; time: F~6,30~ = 51.89, p \< 0.0001; treatment: F~1,5~ = 4.028, p = 0.1010; interaction: F~6,30~ = 1.878, p = 0.1175), but not *5-HT*~*2C*~*R*^*KO*^ mice. Data are presented as mean ± SEM. Sidak\'s post hoc comparisons ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.NTS, nucleus of the solitary tract; AP, area postrema; CC, central canal; DMV, dorsal motor nucleus of the vagus. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Consistent with previous reports, body weight was significantly higher in adult *5-HT*~*2C*~*R*^*KO*^ compared with *5-HT*~*2C*~*R*^*WT*^ mice ([@bib30], [@bib40]); an effect that failed to normalize following post-developmental re-expression of the 5-HT~2C~R exclusively within the NTS/DMV ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Further analysis of energy balance revealed no difference in daily, nocturnal, or diurnal energy expenditure between genotypes ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). We were unable to detect the predicted increase in *ad libitum* chow intake ([Figure S2](#mmc1){ref-type="supplementary-material"}D) or chow intake following an overnight fast in *5-HT*~*2C*~*R*^*KO*^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}E), which may be related to the previously reported variability in the magnitude of hyperphagia on a chow diet with age in *5-HT*~*2C*~*R*^*KO*^ mice ([@bib38]). These results indicate that restoration of 5-HT~2C~Rs only within the NTS/DMV is not sufficient to correct the increased body weight phenotype of chow-fed *5-HT*~*2C*~*R*^*KO*^ mice.

To test the significance of *5-HT*~*2C*~*R*^*NTS/DMV*^ in a therapeutic context, we treated *5-HT*~*2C*~*R*^*WT*^, *5-HT*~*2C*~*R*^*KO*^, and *5-HT*~*2C*~*R*^*NTS/DMV*^ mice with 5-HT~2C~R agonists lorcaserin and WAY161,503. In line with previous research ([@bib8], [@bib17]), the obesity medication lorcaserin and the preclinical compound WAY161,503 significantly reduced *ad libitum* food intake in *5-HT*~*2C*~*R*^*WT*^ mice compared with saline treatment ([Figure 2](#fig2){ref-type="fig"}F). This effect was absent in *5-HT*~*2C*~*R*^*KO*^ mice but predominantly restored in *5-HT*~*2C*~*R*^*NTS/DMV*^ mice ([Figure 2](#fig2){ref-type="fig"}F). Thus, consistent with chemogenetic activation of 5-HT~2C~R^NTS^ cells, pharmacological activation of this discrete subset of cells has a significant impact on feeding behavior. These data also reveal that 5-HT~2C~Rs expressed within the NTS/DMV are sufficient to mediate acute therapeutic effects of a medication currently in clinical use to treat obesity, thereby highlighting a specific subset of 5-HT~2C~Rs that may be exploited for future obesity medication development.

5-HT~2C~R Agonists Directly Activate POMC^NTS^ Cells {#sec2.3}
----------------------------------------------------

We next interrogated the neurochemical phenotype of 5-HT~2C~R^NTS^ cells to probe the mechanism through which 5-HT~2C~R^NTS^-mediated effects on appetite are achieved. Though POMC neurons within the ARC have been proposed to be a primary mediator of 5-HT~2C~R\'s effects on metabolic functions ([@bib5], [@bib8], [@bib11], [@bib14], [@bib19], [@bib41]), a smaller and less well characterized population of POMC expressing neurons reside within the caudal aspect of the NTS (POMC^NTS^), a region receiving inputs from vagal afferent fibers that transmit meal-related information from the gastrointestinal system ([@bib2], [@bib16], [@bib23], [@bib42]). We thus hypothesized that POMC^NTS^ is a functional component of 5-HT~2C~R^NTS^-mediated hypophagia.

To visualize anatomical expression, we utilized *Pomc*^DsRED^ reporter mice ([@bib21]) and fluorescent *in situ* hybridization to label endogenous *5-HT*~*2C*~*R* mRNA. Although more than one-third (38.2% ± 1.3%) of POMC^NTS^ cells express *5-HT*~*2C*~*R* mRNA, POMC^NTS^ neurons represent only a small (approximately 4%) subset of the total NTS *5-HT*~*2C*~*R* mRNA-expressing population ([Figure 3](#fig3){ref-type="fig"}A). Next, to evaluate the impact of 5-HT~2C~R activation on POMC^NTS^ neuronal activity, we performed whole-cell electrophysiological recordings in *Pomc*^DsRED^ NTS slices. Consistent with the anatomical co-expression profile, 45.5% (10/22) of *Pomc*^DsRED^ cells were responsive to 5-HT (10 μM), the endogenous 5-HT~2C~R agonist ([Figures 3](#fig3){ref-type="fig"}B and 3C). A similar proportion of responders was observed following application of 5-HT~2C~R agonists lorcaserin (20 μM) and WAY161,503 (20 μM), with 47.1% (8/17) and 50% (11/22) of *Pomc*^DsRED^ cells responding, respectively ([Figures 3](#fig3){ref-type="fig"}B and 3C). All responses were characterized by depolarization and commencement/enhancement of action potential discharge. These effects were independent of action potential-dependent synaptic transmission, as depolarizations endured in the presence of 500 nM tetrodotoxin (TTX) (5-HT, 13.2 ± 3.8 mV, n = 7; lorcaserin, 11.7 ± 3.6 mV, n = 7; WAY161,503, 12.8 ± 2.7 mV, n = 8; [Figure 3](#fig3){ref-type="fig"}C), indicating that 5-HT and 5-HT~2C~R agonists directly activate POMC^NTS^ cells via a post-synaptic mechanism. 5-HT and 5-HT~2C~R agonists induced a similar degree of depolarization and activated a similar percentage of POMC^NTS^ cells ([Figure 3](#fig3){ref-type="fig"}D). These data reveal that 5-HT~2C~Rs are anatomically positioned to increase the activity of a subset of POMC^NTS^ cells.Figure 35-HT and 5-HT~2C~R Agonists Directly Activate POMC^NTS^ Neurons(A) Representative image illustrating 38% of DsRED-positive POMC^NTS^ neurons (red) express *5-HT*~*2C*~*R* mRNA (green; co-expressed, yellow) in *Pomc*^DsRED^ mice. Scale bar, 200 μm; inset scale bar, 50 μm.(B) Representative current-clamp recordings of POMC^NTS^ neurons in slices from *Pomc*^DsRED^ mice following (i) 10 μM 5-HT, (ii) 20 μM lorcaserin, (iii) and 20 μM WAY161,503.(C) (i) 5-HT (n = 7; F~2,18~ = 12.9, p = 0.001), (ii) lorcaserin (n = 7; F~2,18~ = 8.2, p = 0.006), and (iii) WAY161,503 (n = 8; F~2,21~ = 10.3, p = 0.002) elicit a significant and reversible change in membrane potential (recorded in 500 nM TTX and from an initial membrane potential of −65 mV, a value achieved through the injection of DC current). Thick lines represent mean ± SEM; dashed lines, raw data. ^∗∗∗^p \< 0.001.(D) Summary of membrane potential changes induced by 5-HT, lorcaserin, and WAY161,503. Boxes represent 25th, 50th, and 75th percentile with superimposed mean ± SEM and maximum and minimum values.NTS, nucleus of the solitary tract; AP, area postrema; CC, central canal.

To examine the post-synaptic ionic mechanisms underpinning the excitatory effects of 5-HT and lorcaserin, we recorded POMC^NTS^ neurons in a voltage clamp (VC) and in the presence of TTX. At a holding potential of −60 mV, application of 5-HT (10 μM) induced a reversible inward current of −23.1 ± 2.5 pA (n = 10; [Figure 4](#fig4){ref-type="fig"}A). The current-voltage relationship of I~5-HT~ was examined using VC ramps, which drove the membrane potential from −120 mV to 0 mV at a rate of 45.7 mV s^−1^ ([Figure 4](#fig4){ref-type="fig"}B; n = 10). The digital subtraction of the ramp in control from the ramp at the peak of the response revealed I~5-HT~ to be outwardly rectifying and to reverse at −27.0 ± 3.6 mV ([Figure 4](#fig4){ref-type="fig"}C; n = 10). Likewise, lorcaserin (20 μM) induced an inward current of −15.5 ± 2.5 pA (n = 12; [Figure 4](#fig4){ref-type="fig"}D) that was shown to be outwardly rectifying and to reverse at −24.6 ± 2.9 mV ([Figures 4](#fig4){ref-type="fig"}E and 4F). These data illustrate that 5-HT and lorcaserin excite POMC^NTS^ neurons via the activation of a post-synaptic, mixed cationic current. This mechanism is consistent with that observed for 5-HT~2C~R activation of POMC^ARC^ neurons ([@bib34]).Figure 45-HT and 5-HT~2C~R Agonists Activate POMC^NTS^ Neurons Via Post-synaptic, Mixed Cationic Current(A) Representative voltage-clamp recording of a POMC^NTS^ neuron from *Pomc*^DsRED^ NTS slices in the presence of TTX (500 nM). Application of 5-HT (10 μM) results in an inward current (scale bar, 20 s). To the right, sharing its y axis with the raw trace, are Gaussian fits of averaged (solid lines) holding current frequency distributions in control (green), 5-HT (red), and wash (black). Raw data used to produce averages shown as dashed lines (n = 10, F~2,27~ = 18.1, p = 1.02 × 10^−5^; post hoc Tukey test, ^∗∗∗^p \< 0.001).(B) Averaged voltage-clamp ramps (n = 10) acquired in control (green) and at the peak of response (red). Line denotes mean, shading the SEM.(C) 5-HT-induced current (I~5-HT~) obtained by the digital subtraction of the traces displayed in (B). Note the reversal at −27.0 ± 3.6 mV (n = 10). Line denotes mean, shading the SEM.(D) Representative voltage-clamp recording of a POMC^NTS^ neuron in the presence of TTX. Application of lorcaserin (20 μM) results in an inward current (scale bar, 20 s). To the right, sharing its y axis with the raw trace, are Gaussian fits of averaged (solid lines) holding current frequency distributions in control (green) and lorcaserin (blue). Raw data used to produce averages shown as dashed lines (n = 13, t~12~ = 6.2, p = 4.5 × 10^−5^, t-test paired, ^∗∗∗^p \< 0.001).(E) Averaged voltage-clamp ramps (n = 12) acquired in control (green) and at the peak of response (blue). Line denotes mean, shading the SEM.(F) Lorcaserin-induced current (I~Lorcaserin~) obtained by the digital subtraction of the traces displayed in (E). Note the reversal at −24.6 ± 2.9 mV (n = 12). Line denotes mean, shading the SEM.

Brain POMC Is Necessary to Mediate 5-HT~2C~R Agonist Feeding Effects {#sec2.4}
--------------------------------------------------------------------

Thus far, we have established that the 5-HT~2C~Rs are anatomically positioned to influence the activity of approximately 40% of POMC^NTS^ neurons and previous reports indicate that 5-HT~2C~Rs are co-expressed with approximately 40% of POMC^ARC^ neurons ([@bib19], [@bib27]). Earlier transgenic approaches have revealed that the subset of 5-HT~2C~Rs that are necessary and sufficient for 5-HT~2C~R agonists to reduce food intake are co-expressed with POMC ([@bib5], [@bib40]). These approaches manipulate the expression of the receptor, not POMC production. We aimed to determine the function of POMC in lorcaserin\'s anorectic effect. As a first step toward this goal, we employed a mouse model with full POMC^ARC^ knockout and approximately half POMC^NTS^ knockdown (*Pomc*^*NEO*^) ([@bib7]). *Pomc*^*NEO*^ and wild-type (*Pomc*^*WT*^) littermates were treated with saline or lorcaserin (7 mg/kg, i.p.) at the onset of the dark cycle and *ad libitum* home cage chow intake was measured 1, 3, and 6 hr later. As expected, *Pomc*^*WT*^ mice treated with lorcaserin significantly reduced food intake compared with saline-treated littermates at each time point ([Figure 5](#fig5){ref-type="fig"}A). However, lorcaserin did not have a significant effect on food intake at any of these time points in *Pomc*^*NEO*^ mice compared with saline-treated littermates ([Figure 5](#fig5){ref-type="fig"}B). These results were replicated in further cohorts of *Pomc*^*NEO*^ and *Pomc*^*WT*^ littermates using a within-subjects experimental design (data not shown). These data reveal that brain POMC is required for lorcaserin to promote its effects on food intake.Figure 5Brain POMC Is a Necessary Neurochemical Mediating 5-HT~2C~R Agonist Feeding Effects(A) Male and female wild-type mice (*Pomc*^*WT*^) treated with lorcaserin (7 mg/kg, i.p.) significantly reduced 1-, 3-, and 6-hr dark cycle food intake compared with saline-treated *Pomc*^*WT*^ littermates (n = 11 per group; 1 hr: t~20~ = 2.884, p = 0.0092; 3 hr: t~20~ = 2.916, p = 0.0085; 6 hr: t~20~ = 3.373, p = 0.0030).(B) In contrast, male and female mice with full POMC^ARC^ knockout and partial POMC^NTS^ knockdown (*Pomc*^*Neo*^) exhibited a blunted response to lorcaserin treatment as compared with *Pomc*^*Neo*^ littermates treated with saline (n = 6--7 per group; 1 hr: t~11~ = 1.3204, p = 0.216; 3 hr: t~11~ = 0.4098, p = 0.6898; 6 hr: t~11~ = 0.9486, p = 0.3632).Data are presented as mean ± SEM. ^∗∗^p \< 0.01.

POMC^ARC^ Is Required for the Full Effect of 5-HT~2C~R Agonist on Food Intake {#sec2.5}
-----------------------------------------------------------------------------

We next sought to determine the functional significance of the discrete subset of POMC^NTS^ versus POMC^ARC^ in 5-HT~2C~R agonist-induced reduction of food intake. We first targeted *Pomc* in the hypothalamus, since this population of *Pomc* expressing neurons is larger, better characterized, and projects widely within the hypothalamus, allowing efficient tissue sampling and recovery of peptides that localize at neuron terminals (e.g., POMC-derived peptide α-melanocyte-stimulating hormone \[α-MSH\] \[[@bib12]\]). To knock down POMC^ARC^, we employed the clustered, regularly interspaced, short palindromic repeats (CRISPR) and associated endonuclease 9 (Cas9) gene-editing technique ([@bib15], [@bib22]). Specifically targeted by synthetic guide RNA (sgRNA) sequences, Cas9-induced double-stranded breaks typically result in frameshifting insertion/deletions (indels) owing to the action of non-homologous end-joining (NHEJ) DNA repair mechanisms, leading to disruption of the encoded protein. Following an *in vitro* screening of selected sgRNAs targeting the third exon of the *Pomc* gene, Cas9-induced indels at the predicted positions were detected using a T7 endonuclease I assay ([Figure 6](#fig6){ref-type="fig"}A). Two active sgRNAs were cloned into an AAV vector that also expressed eGFP to enable site-specific brain delivery ([@bib36]).

AAVs expressing *Pomc*-targeting Cas9 and sgRNA-eGFP (*Pomc*^ARC-CRISPR^) or AAVs expressing sgRNA-eGFP alone (*Pomc*^ARC-WT^) were then stereotactically injected into the ARC ([Figure 6](#fig6){ref-type="fig"}B). Quantitative analysis of hypothalamic α-MSH content revealed *Pomc*^ARC-CRISPR^ mice had an approximately 60% reduction in α-MSH ([Figure 6](#fig6){ref-type="fig"}C). To control for the occurrence of CRISPR/Cas9-induced indels, we implemented a method allowing *ex vivo* detection of DNA heteroduplexes. This is a widely used proxy of indel occurrence *in vitro*. Genomic DNA from *Pomc*^ARC-CRISPR^ and *Pomc*^ARC-WT^ mice was extracted and the third exon of the *Pomc* gene was amplified by PCR. Subsequent PAGE analysis revealed that DNA heteroduplexes were exclusively in samples obtained from the mediobasal hypothalamus in *Pomc*^ARC-CRISPR^ mice. DNA heteroduplexes were not found in the hypothalamus of *Pomc*^ARC-WT^ mice ([Figure 6](#fig6){ref-type="fig"}D). Behaviorally, *Pomc*^ARC-CRISPR^ mice displayed phenotypes consistent with reduced POMC^ARC^ function, including hyperphagia following food deprivation ([Figure 6](#fig6){ref-type="fig"}E) and greater operant responding for palatable food ([Figure 6](#fig6){ref-type="fig"}F). Next, we assessed the role of POMC^ARC^ in lorcaserin\'s effects on food intake. As expected, lorcaserin significantly reduced *ad libitum* dark cycle food intake compared with saline treatment in *Pomc*^ARC-WT^ mice when analyzed over the first 3 hr of the dark cycle ([Figure 6](#fig6){ref-type="fig"}G, left) and as cumulative 3 and 6 hr of food intake ([Figure 6](#fig6){ref-type="fig"}G, right). In contrast, *Pomc*^ARC-CRISPR^ mice only significantly responded to the acute anorectic effect of lorcaserin ([Figure 6](#fig6){ref-type="fig"}H, left). Analysis of 3- and 6-hr cumulative intake revealed that *Pomc*^ARC-CRISPR^ mice exhibited an attenuated response to lorcaserin. Specifically, lorcaserin did not significantly alter food intake compared with saline treatment at either time point in *Pomc*^ARC-CRISPR^ mice ([Figure 6](#fig6){ref-type="fig"}H, right). One interpretation of these data is that POMC^ARC^ is not a principal mediator of lorcaserin\'s acute effects on food intake; rather, it is necessary for the longer-term effect. However, it is possible that the acute response to lorcaserin in *Pomc*^ARC-CRISPR^ mice is due to incomplete knockdown of POMC^ARC^ and that the subset remaining is sufficient for lorcaserin to reduce feeding at this earlier time point. Nevertheless, these data indicate that lorcaserin requires functional *Pomc* within the ARC to promote its full effect on food intake.Figure 6Pomc^ARC^ Is Required for 5-HT~2C~R Agonist Hypophagia(A) Representative screening of sgRNAs targeting the exon 3 of the *Pomc* gene in Neuro2A cells and indels detection using a T7 endonuclease I assay. (A, left) Sites of potential indels in exon 3 are indicated by red or green bars, and the presence of indels results in the fragments indicated by red or green asterisks, respectively, following endonuclease treatment. (A, right) Bands corresponding to these fragments are indicated with red and green asterisks on the gel.(B) Schematic of bilateral mediobasal hypothalamic stereotactic delivery of AAVs expressing *Pomc*-targeting CRISPR/Cas9 and EGFP (*Pomc*^ARC-CRISPR^). Representative image of GFP within the arcuate nucleus of the hypothalamus (ARC) third ventricle (3V).(C) Hypothalamic content of *Pomc* peptide product α-melanocyte-stimulating hormone (α-MSH) 6 weeks after AAV injection is significantly reduced as measured by quantitative fluorescent EIA assay in *Pomc*^ARC-CRISPR^ mice compared with controls injected with AAV-expressing sgRNA-eGFP alone (*Pomc*^ARC-WT^), illustrating that *in vivo* CRISPR targeting knocked down *Pomc* in the ARC (p = 0.0059; Mann-Whitney test).(D) PAGE analysis identified heteroduplexes (pink arrowheads) from exon 3 of *Pomc* amplified from the mediobasal hypothalamus of *Pomc*^ARC-CRISPR^ mice.(E) *Pomc*^ARC-CRISPR^ mice exhibit 24 hr of hyperphagia for home cage chow following food restriction compared with *Pomc*^ARC-WT^ mice (n = 7--8; F~1,13~ = 11.27, p = 0.005).(F) Likewise, *Pomc*^ARC-CRISPR^ mice show greater motivation to work for palatable food compared with *Pomc*^ARC-WT^ mice as assessed by the breakpoint of lever presses for chocolate pellets using a progressive-ratio schedule (n = 7--8; t~12~ = 2.463, p = 0.029).(G) (Left) Lorcaserin (7 mg/kg, i.p.) reduced acute food intake within the first 3 hr (tick marks on x axis represent 20-min intervals) of the dark cycle in *Pomc*^ARC-WT^ mice (n = 7; time: F~9,54~ = 38.05, p \< 0.0001; treatment: F~1,6~ = 39.94, p = 0.0007; interaction: F~9,54~ = 13.91, p \< 0.0001) and (right) as analyzed as total 3- and 6-hr cumulative intake (time: F~1,6~ = 169.7, p \< 0.0001; treatment: F~1,6~ = 11.22, p = 0.0154; interaction: F~1,6~ = 0.8351, p = 0.3960).(H) (Left) Lorcaserin (7 mg/kg, i.p.) also reduced acute food intake within the first 3 hr in *Pomc*^ARC-CRISPR^ mice (n = 10; time: F~9,81~ = 168.1, p \< 0.0001; treatment: F~1,9~ = 16.46, p = 0.0029; interaction: F~9,81~ = 2.108, p = 0.0381). (Right) However, lorcaserin was not effective in reducing cumulative food intake compared with saline treatment in *Pomc*^ARC-CRISPR^ mice when analyzed at 3 or 6 hr food intake with Sidak\'s post hoc comparisons (n = 10; time: F~1,9~ = 130.8, p \< 0.0001; treatment: F~1,9~ = 110.44, p = 0.0103; interaction: F~1,9~ = 0.01045, p = 0.9208).Data are presented as mean ± SEM. Sidak\'s post hoc comparisons ^∗^p \< 0.05, ^∗∗^p \< 0.01.

POMC^NTS^ Is Required for the Acute Effect of 5-HT~2C~R Agonists on Food Intake {#sec2.6}
-------------------------------------------------------------------------------

We next examined the functional significance of POMC^NTS^ in the therapeutic effects of 5-HT~2C~R agonist obesity medications. We created two cohorts of mice by stereotactically delivering AAVs expressing *Pomc*-targeting Cas9 and sgRNA-eGFP (*Pomc*^NTS-CRISPR^) or AAVs expressing sgRNA-eGFP alone (*Pomc*^NTS-WT^) to the NTS ([Figures 7](#fig7){ref-type="fig"}A and 7B). Since α-MSH expression from NTS explants is not at a high enough level for reliable measurement, we adopted the method used above for *Pomc*^ARC-CRISPR^ validation, allowing *ex vivo* detection of DNA heteroduplexes to control for the occurrence of CRISPR/Cas9-induced indels. Genomic DNA from *Pomc*^NTS-CRISPR^ and *Pomc*^NTS-WT^ mice was extracted and the third exon of the *Pomc* gene was amplified by PCR. Subsequent PAGE analysis revealed that DNA heteroduplexes were exclusively in samples obtained from the NTS/DMV and not an internal control region in *Pomc*^NTS-CRISPR^ mice ([Figures 7](#fig7){ref-type="fig"}C and 7D). As expected, DNA heteroduplexes were not found in either the NTS/DMV or an internal control region of *Pomc*^NTS-WT^ mice ([Figure 7](#fig7){ref-type="fig"}C). These data suggest that *Pomc* has been successfully targeted in *Pomc*^NTS-CRISPR^ mice, although this method does not provide quantification of the degree of knockdown. As expected, lorcaserin and WAY161,503 significantly reduced *ad libitum* dark cycle food intake in *Pomc*^NTS-WT^ mice over 6 hr ([Figures 7](#fig7){ref-type="fig"}E and 7G). However, following administration of 5-HT~2C~R agonists, *Pomc*^*NTS-CRISPR*^ mice exhibited an attenuated anorectic response to both lorcaserin and WAY161,503 during the first 3 hr of the dark cycle ([Figure 7](#fig7){ref-type="fig"}F). This attenuated effect to lorcaserin and WAY161,503 did not persist for the full 6 hr in *Pomc*^NTS-CRISPR^ mice. Lorcaserin significantly reduced 6-hr cumulative intake in *Pomc*^NTS-CRISPR^ mice compared with saline treatment ([Figure 7](#fig7){ref-type="fig"}H). Taken together with the *Pomc*^*NEO*^ and *Pomc*^ARC-CRISPR^ results, these data suggest that POMC^NTS^ is required for the acute effect of lorcaserin on food intake, whereas POMC^ARC^ is required for the longer-term effect on feeding. These findings are generally consistent with previous reports using chemogenetic and optogenetic approaches to examine POMC neuron function, which suggest that POMC^ARC^ and POMC^NTS^ neurons affect feeding on different time scales ([@bib1], [@bib25], [@bib42]).Figure 7Pomc^NTS^ Is Required for 5-HT~2C~R Agonist Hypophagia(A) AAV-mediated strategy to express in the nucleus of the solitary tract (NTS) *Pomc*-targeting sgRNAs and Cas9. Schematic of bilateral NTS stereotactic delivery of AAVs expressing *Pomc*-targeting CRISPR/Cas9 and EGFP (*Pomc*^NTS-CRISPR^).(B) Representative image of eGFP expression within the dorsal vagal complex (DVC).(C) PAGE analysis identified heteroduplexes (pink arrowheads) from exon 3 of *Pomc* amplified from the DVC of *Pomc*^NTS-CRISPR^ mice.(D) Representative image of tissue samples taken from the NTS and broader dorsal vagal complex (DVC) and an internal control region (Int Ctrl).(E and F) 5-HT~2C~R agonists lorcaserin and WAY161,503 (7 mg/kg, i.p.) reduced acute food intake in control *Pomc*^NTS-WT^ mice (E) within the first 3 hr (tick marks on x axis represent 20-min intervals) of the dark cycle (lorcaserin, n = 8; time: F~9,63~ = 102.2, p \< 0.0001; treatment: F~1,7~ = 18.55, p = 0.0035; interaction: F~9,63~ = 6.245, p \< 0.001. WAY161,503, n = 8; time: F~9,63~ = 54.95, p \< 0.0001; treatment: F~1,7~ = 24.28, p = 0.0017; interaction: F~9,63~ = 3.369, p = 0.0020), but not in *Pomc*^NTS-CRISPR^ mice (F) (lorcaserin, n = 7; time: F~9,54~ = 38.39, p \< 0.0001; treatment: F~1,6~ = 0.1580, p = 0.7048; interaction: F~9,54~ = 0.2533, p = 0.9841. WAY161,503, n = 7; time: F~9,54~ = 62.69, p \< 0.0001; treatment: F~1,6~ = 2.444, p = 0.1690; interaction: F~9,54~ = 0.7558, p = 0.6567).(G) Likewise, when analyzed as total cumulative 3- and 6-hr dark cycle intake, lorcaserin and WAY161,503 significantly reduced food intake in control *Pomc*^NTS-WT^ mice (lorcaserin, n = 8; time: F~1,7~ = 96.71, p \< 0.0001; treatment: F~1,7~ = 70.40, p \< 0.0001; interaction: F~1,7~ = 0.6355, p = 0.4515. WAY161,503, n = 8; time: F~1,7~ = 62.88, p \< 0.0001; treatment: F~1,7~ = 17.53, p = 0.0041; interaction: F~1,7~ = 4.238, p = 0.0785).(H) POMC^NTS^ knockdown in *Pomc*^NTS-CRISPR^ mice prevented the acute 3-hr anorectic effect of 5-HT~2C~R agonists, but was not sufficient to prevent the full effect 6 hr post treatment as analyzed with Sidak\'s post hoc comparisons (lorcaserin, n = 7; time: F~1,6~ = 92.76, p \< 0.0001; treatment: F~1,6~ = 2.823, p = 0.1439; interaction: F~1,6~ = 5.309, p = 0.0608. WAY161,503, n = 7; time: F~1,6~ = 66.68, p = 0.0002; treatment: F~1,6~ = 4.152, p = 0.00877; interaction: F~1,6~ = 4.005, p = 0.0923).Data are presented as mean ± SEM. Sidak\'s post hoc comparisons ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Discussion {#sec3}
==========

Obesity negatively affects human health on a global scale. If we are to meet this challenge and design new medications, it is paramount that we gain a more complete understanding of the mechanisms regulating food intake and body weight. The 5-HT~2C~R agonist lorcaserin is a current obesity medication; however, neither the specific subset of 5-HT~2C~Rs coordinating the therapeutic effect nor the neurochemical mediator targeted by these receptors has been fully defined. Earlier research genetically manipulating the receptor revealed that the subset of 5-HT~2C~Rs co-expressed with brain POMC are both sufficient ([@bib41]) and necessary ([@bib5]) to modulate the anorectic effect of preclinical 5-HT~2C~R agonists. Given that 5-HT~2C~R agonists increase the activity of POMC^ARC^ neurons ([@bib10], [@bib14], [@bib19]), it was presumed that these neurons were the mediator of this effect. However, in light of recent findings that POMC^ARC^ neurons suppress appetite on a time scale of hours ([@bib1], [@bib25], [@bib42]), we considered whether 5-HT~2C~Rs outside the ARC are necessary for 5-HT~2C~R\'s acute effects on feeding. Here we identify the function of a previously uncharacterized subset of 5-HT~2C~R expressing neurons, localized within the NTS, and reveal that the activation of this subpopulation has a significant and rapid impact on feeding behavior, and furthermore is sufficient to drive lorcaserin\'s acute reduction in food intake. In addition, we report that a subset of POMC^NTS^ neurons express 5-HT~2C~Rs and that 5-HT and 5-HT~2C~R agonists directly activate POMC^NTS^ neurons via a post-synaptic, mixed cationic current. We also clarify that brain POMC is necessary for lorcaserin to influence feeding. Although POMC is not abundantly expressed within the NTS, we report that POMC in this region is required for 5-HT~2C~R agonist obesity medications to acutely reduce food intake. These data thereby reveal a subpopulation of 5-HT~2C~Rs, which when pharmacologically activated significantly reduce food intake, identify that the mechanistic underpinnings of this acute effect is via POMC^NTS^, and demonstrate that this discrete 5-HT~2C~R^NTS^ subpopulation is therapeutically relevant to obesity medications targeting the 5-HT~2C~Rs.

Limitations of Study {#sec3.1}
--------------------

It is possible that the results obtained are affected by incomplete knockdown of *Pomc* in the ARC and NTS. Although altering POMC^NTS^ expression significantly attenuated the acute effect of lorcaserin on food intake, at baseline *Pomc*^NTS-CRISPR^ mice displayed food intake comparable with *Pomc*^NTS-WT^ mice during *ad libitum* feeding ([Figures 7](#fig7){ref-type="fig"}E and 7F; and data not shown). These data are consistent with a previous report of diphtheria toxin POMC^NTS^ cell ablation in a *Pomc*^*Cre*^ mouse line, which did not produce an effect on *ad libitum* food intake ([@bib42]). However, we cannot exclude the possibility that this absence of baseline phenotype *Pomc*^NTS-CRISPR^ mice is due to incomplete knockdown of *Pomc*^NTS^. Further studies are required to fully interrogate the physiological role of POMC^NTS^. Nevertheless, our data reveal that the relatively small source of POMC specifically derived within the NTS is necessary for the obesity medication lorcaserin and the preclinical compound WAY161,503 to promote their full effects on feeding behavior.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Chicken anti-GFPAbCamCat\# ab13970; RRID: [AB_300798](nif-antibody:AB_300798){#intref0010}Rabbit anti-dsREDRocklandCat\# 600-401-379; RRID: RRID: AB_2209751Rabbit anti-c-FOSCalbiochemCat\# PC38; RRID:[AB_2106755](nif-antibody:AB_2106755){#intref0015}Goat mCherry (RFP)SicgenCat\# AB0040-200; RRID:[AB_2333092](nif-antibody:AB_2333092){#intref0020}Donkey polyclonal anti-chicken alexa 488Jackson ImmunoResearchCat\# 703-545-155; RRID: [AB_2340375](nif-antibody:AB_2340375){#intref0025}Goat anti-Rabbit IgG Secondary Antibody, Alexa Fluor 594Life TechnologiesCat\# A-11012, RRID:[AB_141359](nif-antibody:AB_141359){#intref0030}Donkey anti-Goat IgG Secondary Antibody, Alexa Fluor 594Life TechnologiesCat\# A-11057; RRID:[AB_142581](nif-antibody:AB_142581){#intref0035}Biotin-SP-AffiniPure F(ab\')2 Fragment Donkey Anti-Rabbit IgGJackson ImmunoResearchCat\# 711-066-152, RRID:[AB_2340594](nif-antibody:AB_2340594){#intref0040}Streptavidin, Alexa Fluor® 568 conjugate antibodyLife TechnologiesCat\# S-11226, RRID:[AB_2315774](nif-antibody:AB_2315774){#intref0045}**Bacterial and Virus Strains**One Shot® Stbl3™ Chemically Competent *E*. *coli*InvitrogenCat\# C737303AAV8-hSyn-DIO-hM3D~q~-mCherryUniversity North Carolina Vector CoreN/AAAV8-hSyn-DIO-hM4D~i~-mCherryUniversity North Carolina Vector CoreN/AAAV8-hSyn-mCherry-CreUniversity North Carolina Vector CoreN/AAAV-U6sgRNA(SapI)\_hSyn-GFP-KASH-bGHUnitat de Producció de Vectors, Universitat Autonoma Barcelona, SpainN/AAAV/DJ-CMV-spCas9Vector BiolabsCat\# 7120**Chemicals**, **Peptides**, **and Recombinant Proteins**Clozapine-N-oxide (CNO)Tocris BioscienceCat. No. 4936; CAS: 34233-69-7Lorcaserin HydrochlorideLGM PharmaCat\# 846589-98-8\
Lot\# 20130115WAY 161503 hydrochlorideTocris BioscienceCat. No. 1801; CAS: 276695-22-8**Critical Commercial Assays**In-Fusion HD cloning KitClonotech LaboratoriesCat No. 638910Plasmid plus Maxi kitQIAGENCat No. 12943QIAquick Gel Extraction KitQIAGENCat No. 28704FuGENE HD Transfection ReagentPromegaCat No E2311PureLink Genomic DNA Mini KitInvitrogenCat No K182001Surveyor Mutation Detection KitIntegrated DNA TechnologiesCat No. 706020MSH, alpha EIA kitPhoenix Pharmaceutical Inc.Cat No FEK-043-01**Experimental Models**: **Cell Lines**Neuro-2a (N2a) cellsATCCCCL-131**Experimental Models**: **Organisms/Strains**Mouse: *5-HT*~*2C*~*R-ires*^*Cre*^[@bib9], [@bib29]N/AMouse: *POMC*^*dsRed*^[@bib21]N/AMouse: *POMC*^*NEO*^[@bib7]N/AMouse: *loxtb5-HT*~*2C*~*R* (B6.129-Htr2c^tm1Jke^/J)Jackson LaboratoryJAX: 015821Mouse: C57BL/6JJackson LaboratoryJAX: 000664**Oligonucleotides**Genomic DNA *Pomc* PCR primer F:\
GCTTGCATCCGGGCTTGCThis paperN/Agenomic DNA *Pomc* PCR primer R:\
GACTTTATTTACGCAGTTTTTATTGAAGATCAGAGCThis paperN/A*Pomc* gRNA1:\
GGTGGGCAAGAAACGGCGCCThis paperN/A*Pomc* gRNA2:\
GTGACCCATGACGTACTTCCGThis paperN/A**Recombinant DNA**pX330-U6-Chimeric_BB-CBh-hSpCas9 (PX330)AddgeneAddgene Plasmid \#42230pAAV-U6sgRNA(SapI)\_hSyn-GFP-KASH-bGH (PX552)AddgeneAddgene Plasmid \#60958cDNA HTR2C cDNA[@bib24]N/A**Software and Algorithms**pClamp10 softwareMolecular DevicesCRISPR DesignZhang Lab, MIT<http://crispr.mit.edu/>PhenoMasterTSE<https://www.tse-systems.com/product-details/phenomaster>MATLABMathworks<https://www.mathworks.com/>Prism6GraphPad<https://www.graphpad.com/scientific-software/prism/>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for reagents may be directed to the Lead Contact Lora Heisler (<lora.heisler@abdn.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

*5-HT*~*2C*~*R-ires*^*Cre*^ ([@bib9], [@bib29]), *loxtb5-HT*~*2C*~*R* (B6.129-*Htr2c*^tm1Jke^/J; The Jackson Laboratory, Bar Harbor, ME USA), *Pomc*^DsRED^ ([@bib21]) and *Pomc*^*NEO*^ ([@bib7]) mice were housed with *ad libitum* food and water access (unless otherwise stated) in a light- (12 h on/12 h off) and temperature-controlled (21.5°C to 22.5°C) environment. All procedures were performed in accordance with the U.K. Animals (Scientific Procedures) Act 1986 and local ethical approvals.

Method Details {#sec4.4}
--------------

### Stereotaxic Surgery and Viral Vectors {#sec4.4.1}

Viral constructs were packaged in AAV serotype-8 and were delivered to the NTS via bilateral stereotaxic injections, as previously described ([@bib13]).

#### AAV vectors {#sec4.4.1.1}

The DREADD viruses used have been described previously: AAV8-hSyn-DIO-hM3D~q~-mCherry, AAV8-hSyn-DIO-hM4D~i~-mCherry and AAV8-hSyn-mCherry-Cre were packaged in AAV serotype-8 at a titer of 1.3 x 10^13^ vg/ml (University North Carolina Vector Core, Chapel Hill, NC, USA) ([@bib26], [@bib13]). AAV/DJ-CMV-spCas9 was obtained from Vector Biolabs (Cat No. 7120; Vector Biolabs, Malvern, PA, USA). High titer pAAV-U6sgRNA(SapI)\_hSyn-GFP-KASH-bGH (PX552) were packaged in AAV serotype-8 at a titer of 4.1 x 10^12^ vg/ml (Unitat de Producció de Vectors, Universitat Autonoma Barcelona, Spain).

#### Stereotaxic Surgery {#sec4.4.1.2}

NTS delivery of AAVs was achieved through a stereotaxic procedure. Briefly, 5--8 week old male mice were anesthetized with a mixture of ketamine and xylazine dissolved in saline (100 and 10 mg/kg, respectively injected in a volume of 10 ml/kg, i.p.). Mice were placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA USA) using ear bars with the head angled at 45°. Under magnification, an incision was made at the level of the cisterna magna and neck muscles carefully retracted. A 33G needle was used for dura incision. The obex served as reference point for injection. Bilateral injections were performed using a glass micropipette (diameter 20--40 μm). NTS coordinates used were A/P, -0.2; M/L, ±0.2; D/V, -0.2 from the obex. Virus was delivered under air pressure using a PLI-100A Pico-Injector (Harvard Apparatus, Cambridge, UK). 150 nl of virus per side was delivered with multiple microinjections over 4--5 minutes. The pipette remained in place for a minimum of 3 minutes after injection. Following all surgery, animals were closely monitored, kept warm and appropriate postsurgical care was taken. Animals were also administered an analgesic (5 mg/kg carprofen, s.c.) daily for 2 days post-operatively. Prior to experimentation, mice were acclimated to handling and i.p. injections.

Mice were given a minimum of 14 days of surgical recovery before experimentation. For chemogenetic experiments, mCherry was visualised by immunohistochemistry. Mice in which the expression of reporter fluorescent protein was bilaterally detected in the caudal aspect of the DVC were included in the analysis, whereas mice without reporter fluorescent expression or expression outside the DVC were excluded from the analysis. Caudal DVC was defined by the presence of the area postrema in the same section of brain tissue.

#### DNA Constructs {#sec4.4.1.3}

For SpCas9 target selection and generation of single guide RNA (sgRNA), the 20-nt target sequences were selected to precede a 5'-NGG protospacer-adjacent motif (PAM) sequence. To minimize off-targeting effects, the CRISPR design tool was used (<http://crispr.mit.edu/>). The 20-nt target and complement sequences were synthesized to include BbsI overhangs. Oligos were annealed, phosphorylated and ligated into the pX330-U6-Chimeric_BB-CBh-hSpCas9 (PX330; Addgene plasmid \#42230) plasmid after BbsI digestion.

pAAV-U6sgRNA(SapI)\_hSyn-GFP-KASH-bGH (PX552; Addgene plasmid \# 60958) was used for cloning sgRNAs into AAV the backbone and generate viral particles. The plasmid was first digested with SapI to create sticky ends for ligation. The 20-nt target and complement sequences were synthesized to include SapI overhangs and ligated. A second sgRNA was then inserted into this vector. The second sgRNA was first PCR-amplified from PX330. Primers were designed to include 15bp homology arms to the PspOMI-lineraised PX552 into the PCR clone sgRNA guide. The PCR product was column-purified and then cloned into the PspOMI-lineraised PX552 vector via homologous recombination-assisted cloning (In-Fusion HD cloning Kit®, Cat No. 638910; Clonotech Laboratories). Primers sequences: AGACTGCAGAGGGCCGAGGGCCTATTTCCCATGATTCCT, forward; CTCATACGCAGGGCCCTAAAACAAAAAAGCACCGACTCGG, reverse. All obtained constructs were verified by sequencing. All plasmids were amplified using One Shot® Stbl3™ Chemically Competent *E*. *coli* (Cat No. C737303; Invitrogen) and column-purified (Cat No. 270104; Qiagen).

*Pomc* targeting sgRNAs (5' to 3'): sgRNA 1- GGTGGGCAAGAAACGGCGCC(cgg); sgRNA 2- GTGACCCATGACGTACTTCCG(ggg).

#### Cell Line Culture and Transfection {#sec4.4.1.4}

Mouse Neuro-2a (N2a) cells were grown in DMEM containing 10% FBS. Cells were maintained at 37°C in 5% CO~2~ atmosphere. Transfection were performed using FuGENE ® HD Transfection Reagent (Cat No E2311; Promega) according to the manufacturer's protocol. Briefly, 1.5x10^4^ cells per well were plated into a 12 well plate the day before transfection. 1 ug of PX330 plasmid was mixed with Fugene HD in Optimem medium (ratio 1:3). Cells were incubated for 48 hours. Genomic DNA was extracted from transfected cells using PureLink® Genomic DNA Mini Kit (Cat No K182001, Invitrogen) following the manufacturer's instructions.

#### Detection of Insertions/Deletions (*Indels*) {#sec4.4.1.5}

The third exon of the mouse *Pomc* gene was PCR amplified from genomic DNA using the following primers: GCTTGCATCCGGGCTTGC, *forward*; GACTTTATTTACGCAGTTTTTATTGAAGATCAGAGC, *reverse*. This PCR reaction generates a single PCR product of the expected 726bp size. PCR product was sequence verified. To detect sgRNA/spCas9-induced *indels*, genomic DNA from cells was amplified using the same primers and this 726bp product corresponding to third exon of the mouse *Pomc* gene was used for the endonuclease I assay (Surveyor® Mutation Detection Kit; Cat No. 706020; Integrated DNA Technologies) following the manufacturer's instructions. Briefly, PCR amplicons were heat-denaturated and re-annealed using a thermocycler to create DNA heteroduplexes. DNA heteroduplexes were incubated with endonuclease I enzyme, which cleaves DNA at the site of a base mismatch with high specificity, for 1 hour at 42°C. Genomic modifications were verified using gel agarose electrophoresis.

### Feeding Studies {#sec4.4.2}

#### Dark Cycle Food Intake {#sec4.4.2.1}

Mice were injected with vehicle or drug 30 minutes prior to the onset of the dark cycle and food was removed. At the onset of dark, food was returned and manually (home cage) or automatically (Phenomaster chambers, TSE, Bad Homburg, Germany) weighed using methods previously described ([@bib13]).

#### Post-fast Refeeding {#sec4.4.2.2}

Food was removed at the onset of the dark cycle and returned 2 hours after the onset of the light cycle the following day. Food intake was measured manually (home cage) or automatically (TSE Phenomaster chambers) using methods previously described ([@bib13]).

#### Progressive Ratio {#sec4.4.2.3}

Mice were trained in operant chambers housed in sound-attenuating boxes and controlled by a PC Med-PC-IV programming language (MED Associates, Inc., Fairfax, VT USA). Chambers (21.6 cm long × 17.8 cm wide × 12.7 cm high) have a retractable lever, a pellet receptacle and a 3 watt house-light on the opposite wall (Cat No. MED-307W-D1, MED Associates, Inc.). Under food restriction, mice were trained to press the lever for 20 mg chocolate pellet reinforcers (TestDiet, St. Louis, MO USA) under a fixed ratio (FR) 1 schedule for 3 days followed by FR 5 for a further 3 days. Then they were fed *ad libitum* and underwent daily training under a PR schedule based on an exponential progression derived from the formula (5 × e0.2n)−5, rounded to the nearest integer, where n is the position in the ratio sequence ([@bib32]). 50 minute sessions took place at the same time each day during the light phase (between 08:00 and 13:00 hours) for 1 week. The breakpoint or alternatively the highest completed ratio ([@bib31]) was defined as the last ratio completed before 5 minutes elapsed without any responding.

### Immunohistochemistry (IHC) and Fluorescent In Situ Hybridization Histochemistry (FISH) {#sec4.4.3}

*IHC*. Tissue was processed for GFP, mCherry, dsRed and/or c-Fos (FOS-IR) IHC as previously described ([@bib13]). Briefly, mice were transcardially perfused with phosphate buffered saline (PBS) followed by 10% neutral buffered formalin (Sigma-Aldrich). Brains were extracted, post-fixed in 10% neutral buffered formalin at 4°C, cryoprotected in 20% sucrose at 4°C and then sectioned coronally on a freezing sliding microtome at 25 μm. Tissue was processed for chicken anti-GFP (1:1000; AbCam, ab13970), rabbit anti-dsRED (1:1000; Rockland, 600-401-379), goat anti-mCherry/RFP (1:1000; Sicgen, AB0040-200) or anti-c-FOS (1:5000, rabbit, Calbiochem, PC38) primary antibodies and a biotinylated donkey anti-rabbit (1:500, Jackson ImmunoResearch Laboratories, Inc.) or Alexa Fluor (1:500, Life Technologies) secondary antibodies using standard protocols previously described ([@bib28], [@bib20]). Tissue was then mounted on slides, cover slipped and the NTS visualized using an Axioskop II microscope (Carl Zeiss, Oberkochen, Germany) and Adobe Photoshop CS5 software. Images of single-label immuoreactivity (IR) for GFP or mCherry were used to visualize and analyze NTS injection sites.

#### Dual-IHC {#sec4.4.3.1}

Dual-IHC was performed to visualize co-expression of mCherry-IR and FOS-IR in *5-HT*~*2C*~*R*^NTS^-hM3D~q~ mice. Specifically, mice were fasted overnight and then injected with designer drug CNO or saline. Brains were extracted 90 minutes later and dual-label mCherry and FOS-IR performed using method outlined above. Quantitative analysis of single and dual-labelled cells was performed manually using an Axioskop II microscope and Adobe Photoshop CS5 software.

#### IHC and FISH {#sec4.4.3.2}

IHC and FISH were performed to visualize co-expression of POMC and 5-HT~2C~R within the NTS in *POMC*^*dsRED*^ mice. To label *5-HT*~*2C*~*R* expressing neurons, a RNA expression vector (pBluescript SK-) containing the 3-kilobase (kb) coding region of 5-HT~2C~R cDNA was used to generate single-stranded RNA probes ([@bib24]). Briefly, *in vitro* transcription was performed using Digoxigenin (DIG)-RNA Labelling Mix (Roche, Mannheim, Germany). Sections were treated with 1% Sodium Borohydride solution and 0.25% Acetic Anhydride in Triethanolamine (TEA) solution. Sections were then incubated in a hybridization buffer containing a DIG-UTP-labelled 5-HT~2C~R riboprobe overnight at 55°C. Sections were rinsed in a standard sodium citrate/50% formamide solution, rinsed in an RNase (0.02 mg/ml RNase A) solution, incubated in a 3% H~2~O~2~ solution for 30 minutes and blocked in a 2% sheep serum (Sigma-Aldrich, Saint Louis, MO USA). Sections were then incubated with an anti-DIG antibody (1:5000, Roche, Mannheim, Germany), treated with TSA PLUS Biotin Kit (PerkinElmer Inc., Waltham, MA USA) and revealed with streptavidin conjugated Alexa Fluor® 568 (1:2000, Life Technologies, Carlsbad, CA USA). To label POMC, sections were blocked again and incubated with rabbit anti-dsRED (1:1000; Rockland, Limerick, PA USA; 600-401-379) overnight at 4°C using the IHC protocol described above. The sections were incubated with Alexa Fluor® 568 donkey anti-rabbit secondary antibody (1:500, Invitrogen™ Life Technologies, Carlsbad, CA USA) for 1 hour. Tissue was then mounted on slides, cover slipped and single- and dual-labelling assessed in the NTS using an Axioskop II microscope and Adobe Photoshop CS5 software. Quantitative analysis of single and dual-labelled dsRed-IR and *5-HT*~*2C*~*R* mRNA cells was conducted manually.

#### Enzyme Immunoassay (EIA) for Alpha-Melanocyte-Stimulating Hormone (Alpha-MSH) {#sec4.4.3.3}

Mice were anesthetized with sodium pentobarbital (Euthatal) and decapitated. The brain was rapidly removed, the hypothalamus was dissected using razor blades and mouse acrylic brain matrices (Stoelting Co.) and frozen in dry ice. Hypothalamic lysates were obtained using a probe sonicator. Lysis consisted of an acid-ethanol solution obtained by combining 1 part of concentrated HCl with 7 parts pure ethanol. 0.1ml of lysis was used per 10 mg of tissue (weight of each hypothalamic explant was about 30 mg). 10 μl of crude homogenate were combined with 50 μl of fresh lysis buffer and centrifuged 3500 g for 30 min. Supernatants were collected and dried using a vacuum centrifuge in low protein binding tubes (Eppendorf® LoBind, Sigma-Aldrich, Cat No. Z666505). Dry fractions were solubilised in 150 μl of assay buffer and alpha-MSH content analysed using a fluorescent EIA ultra-sensitive assay (Phoenix Pharmaceutical Inc.; Cat No FEK-043-01) following the manufacturer's instructions.

### Electrophysiology and Chemogenetic Validation Analysis {#sec4.4.4}

For electrophysiological experiments, male and female *POMC*^*DS-*Red^ (n=44), male *loxtb5-HT*~*2C*~*R* (n=9), male *5-HT*~*2C*~*R*^NTS^-hM3D~q~ (n=2) or male *5-HT*~*2C*~*R*^NTS^-hM4D~i~ (n=2) mice aged 2-6 months were anesthetized with sodium pentobarbital (Euthatal) and decapitated. The brain was rapidly removed and placed in cold (0--4°C), oxygenated (95%O~2~/5%CO~2~) 'slicing' solution containing (in mM) sucrose (214), KCl (2.5), NaH~2~PO~4~ (1.2), NaHCO~3~ (26), MgSO~4~ (4), CaCl~2~ (0.1), D-glucose (10). The brain was fixed to a vibrating microtome (Campden Instruments, Loughborough, UK) and 200-μm thick coronal sections of the brainstem containing the NTS were prepared. Slices were immediately transferred to a 'recording' solution containing (in mM) NaCl (127), KCl (2.5), NaH~2~PO~4~ (1.2), NaHCO~3~ (26), MgCl~2~ (1.3), CaCl~2~ (2.4) and D-glucose (10) in a continuously oxygenated holding chamber at 35°C for a period of 25 minutes. Slices were remained in the recording solution at room temperature for a minimum of 1 hour before recording. For whole-cell recordings, slices were transferred to a submerged chamber and a Slicescope upright microscope (Scientifica, Uckfield, UK) was used for infrared - differential interference contrast and fluorescence visualization of cells. During recording, slices were continuously perfused at a rate of ca. 2 ml/minute with oxygenated recording solution at room temperature. All pharmacological compounds were bath applied. Whole cell current-clamp recordings were performed with pipettes (3--7 MΩ when filled with intracellular solution) made from borosilicate glass capillaries (World Precision Instruments, Aston, UK) pulled on a Zeitz DMZ micropipette puller (Zeitz Instruments GmBH, Martinsried, Germany). The intracellular recording solution contained (in mM) K-gluconate (140), KCl (10), HEPES (10), EGTA (1), Na~2~ATP (2), pH 7.3 (with KOH). Recordings were performed using a Multiclamp 700B amplifier and pClamp10 software (Molecular Devices, Sunnyvale, CA USA). Liquid junction potential was 16.4 mV and not compensated. The recorded current was sampled at 10 kHz and filtered at 2 kHz unless otherwise stated.

### Drugs {#sec4.4.5}

Lorcaserin (LGM Pharma, Erlanger KY USA), WAY161,503 (Tocris Bioscience, Abingdon UK) and clozapine-n-oxide (CNO; Tocris Bioscience) were prepared in double distilled H~2~O, diluted in sterile phosphate-buffered saline (PBS) and administered *in vivo* i.p. in a volume of 10 ml/kg. 5-HT (Sigma-Aldrich), lorcaserin, WAY161,503 and CNO were dissolved in artificial cerebrospinal fluid (aCSF) for electrophysiology experiments.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Data were analyzed with t-test, Mann Whitney U test, One-way, Two-way or Repeated Measures ANOVA followed by Tukey's or Sidak's *post hoc* tests, where appropriate. For all analyses, significance was assigned at p\<0.05. Data are presented as mean±SEM. All statistical analyses were completed with GraphPad Prism 7.0 (GraphPad Software, San Diego, CA USA).
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